The use of allogenic blood transfusion (ABT) as an alternative means to manage ID may be considered for treating critical anemia (Hb level < 7 g/dl), acute myocardial ischemia, hemodynamically unstable active bleeders, or in the case of treatment failure with the other options1,11–13. Here, GSTM1 is linked to anemia.